Skip to main content
. Author manuscript; available in PMC: 2014 Jun 6.
Published in final edited form as: Ann Surg Oncol. 2012 Dec 1;20(5):1470–1481. doi: 10.1245/s10434-012-2761-0

TABLE 1.

Patient demographics, treatment, and pathology results

Total
N = 117 (%)
FALP
N = 22 (%)
YCU
N = 19 (%)
MSKCC
N = 76 (%)
p
Gender  0.9
 Female 75 (64.1) 15 (68.2) 12 (63.2) 48 (63.2)
 Male 42 (35.9) 7 (31.8) 7 (36.8) 28 (36.8)
Age (years)  0.056
 Median (range) 65 (28–91) 60 (41–91) 63 (48–85) 69 (28–90)
 Mean ± SD 65.4 ± 11.4 60.3 ± 12.3 65.8 ± 10.2 66.8 ± 11.1
Race <0.0001
 Caucasian 58 (49.6) 0 0 58 (76.3)
 Hispanic 26 (22.2) 21 (95.5) 0 5 (6.6)
 Asian-Japanese 19 (16.2) 0 19 (100) 0
 African-American 3 (2.6) 0 0 3 (3.9)
 Pacific Islander 2 (1.7) 0 0 2 (2.6)
 Asian-American 3 (2.6) 0 0 3 (3.9)
 Indian 1 (0.9) 0 0 1 (1.3)
 Native American 1 (0.9) 1 (4.5) 0 0
 Unknown 4 (3.4) 0 0 4 (5.3)
Gallstones <0.0001
 Yes 94 (80.3) 22 (100) 9 (47.4) 63 (82.9)
 No 23 (19.7) 0 10 (52.6) 13 (17.1)
Incidental <0.0001
 Yes 46 (39.3) 12 (54.5) 0 34 (44.7)
 No 71 (60.7) 10 (45.5) 19 (100) 42 (55.3)
Curative resection  0.027
 Yes 71 (60.7) 8 (36.4) 14 (73.7) 49 (64.5)
 No 46 (39.3) 14 (63.6) 5 (26.3) 27 (35.5)
Main procedure  0.002
 Segmentectomy 4B/5 49 (41.9) 7 (31.8) 9 (47.4) 33 (43.4)
 Segmentectomy 4B/5 + PDD 4 (3.4) 1 (4.5) 2 (10.5) 1 (1.3)
 Extended hepatectomy 28 (23.9) 0 6 (31.6) 22 (28.9)
 Cholecystectomy (noncurative) 27 (23.1) 12 (54.5) 0 15 (19.7)
 Cholecystectomy (curative) 5 (4.3) 1 (4.5) 2 (10.5) 2 (2.6)
 Nonresection 4 (3.4) 1 (4.5) 0 3 (3.9)
Hepatic resection <0.0001
 Yes 81 (69.2) 8 (36.4) 17 (89.5) 56 (73.7)
 No 36 (30.8) 14 (63.6) 2 (10.5) 20 (26.3)
Bile duct resection <0.0001
 Yes 56 (47.9) 3 (13.6) 14 (73.7) 39 (51.3)
 No 61 (52.1) 19 (86.4) 5 (26.3) 37 (48.7)
Adjacent organ resection  0.1
 Yes 15 (12.8) 0 3 (15.8) 12 (15.8)
 No 102 (87.2) 22 (100) 16 (84.2) 64 (84.2)
Adjuvant therapy  0.1
 Yes 53 (45.3) 6 (27.3) 11 (57.9) 36 (47.4)
 No 64 (54.7) 16 (72.7) 8 (42.1) 40 (52.6)
T stage  0.001
 1 5 (4.3) 1 (4.5) 1 (5.3) 3 (3.9)
 2 41 (35) 14 (63.6) 5 (26.3) 22 (28.9)
 3 63 (53.8) 6 (27.3) 9 (47.4) 48 (63.2)
 4 5 (4.3) 0 4 (21.1) 1 (1.3)
 Unknown 3 (2.6) 1 (4.5) 0 2 (2.6)
Histology  0.3
 Adenocarcinoma 106 (90.6) 21 (95.5) 17 (89.5) 68 (89.5)
 Adenosquamous 6 (5.1) 1 (4.5) 0 5 (6.6)
 Squamous 2 (1.7) 0 0 2 (2.6)
 Neuroendocrine 2 (1.7) 0 1 (5.3) 1 (1.3)
 Undifferentiated 1 (0.9) 0 1 (5.3) 0
Differentiation <0.0001
 Well 16 (13.7) 1 (4.5) 10 (52.6) 5 (6.6)
 Moderate 61 (52.1) 15 (68.2) 5 (26.3) 41 (53.9)
 Poor 40 (34.2) 6 (27.3) 4 (21.1) 30 (39.5)
Lymphovascular invasion (n = 88)  0.2
 No 42 (47.7) 5 (45.5) 6 (31.6) 31 (53.4)
 Yes 46 (52.3) 6 (54.5) 13 (68.4) 27 (46.6)
Perineural invasion (n = 81)  0.8
 No 30 (37) 4 (40) 8 (42.1) 18 (34.6)
 Yes 51 (63) 6 (60.0) 11 (57.9) 34 (65.4)
Lymph node stage  0.03
 Negative 39 (33.3) 4 (18.2) 4 (21.1) 31 (40.8)
 Positive 64 (54.7) 12 (54.5) 14 (73.7) 38 (50)
 Unknown 14 (12) 6 (27.3) 1 (5.3) 7 (9.2)
Lymph nodes resected <0.0001
 Median (range) 3.5 (0–55) 4 (0–13) 13 (0–55) 3 (0–17)
 Mean ± SD 6.6 ± 9.5 4.6 ±4 19 ± 17 3.9 ± 3.7
Positive lymph nodes  0.019
 Median (range) 1 (1–43) 2 (1–7) 2 (1–43) 1 (1–6)
 Mean ± SD 1.6 ± 4.2 1.3 ± 1.8 4 ± 9.6 1 ± 1.5
TNM stage  0.02
 1 3 (2.6) 0 1 (5.3) 2 (2.6)
 2 10 (8.5) 4 (18.2) 2 (10.5) 4 (5.3)
 3a 21 (17.9) 0 1 (5.3) 20 (26.3)
 3b 37 (31.6) 7 (31.8) 7 (36.8) 23 (30.3)
 4a 3 (2.6) 0 2 (10.5) 1 (1.3)
 4b 43 (36.8) 11 (50) 6 (31.6) 26 (34.2)

PDD pancreaticoduodenectomy